GSC
ZYNE

Ground Swell Capital’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Ground Swell Capital’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,445
Closed -$19K – 152
2022
Q3 		$19K Buy
+25,445
New +$28.9K 0.05% 88

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Ground Swell Capital's ZYNE Position: Q4 2022 in Review

Ground Swell Capital sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 25,445 shares — an estimated $19K sold.

Ground Swell Capital first reported a position in ZYNE in Q3 2022 and held it in 1 quarter. The position peaked at $19K in Q3 2022. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • Ground Swell Capital reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Ground Swell Capital sold 25,445 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $19K.
  • Ground Swell Capital first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2022 and held it in 1 quarter.
  • Ground Swell Capital's Zynerba Pharmaceuticals, Inc position peaked at $19K in Q3 2022.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on Ground Swell Capital's 13F filing for Q4 2022, filed 14 Feb 2023.